BOOK
Novel PET Radiotracers with Potential Clinical Applications, An Issue of PET Clinics, E-Book
(2017)
Additional Information
Book Details
Abstract
This issue of PET Clinics focuses on Radiotracers, and is edited by Drs. Neil Vasdev and Abass Alavi. Articles will include: PET/CT detection of HER2-positive metastases in patients with 89Zr-DFO-trastuzumab; uPAR-PET with 68Ga-NOTA-AE105: first clinical experience with a novel PET ligand; 64Cu-FBP8: A fibrin-targeted probe for imaging of thrombus; Imaging of synaptic density in the brain via synaptic vesicle glycoprotein 2A (SV2A) with a novel biomarker [11C]UCB-J; Neuroimaging of stress sensitive and neuroinflammatory targets in mood disorders; Impact of MR-based PET motion correction on the quantification of PET kinetic parameters in simultaneous cardiac PET-MR; Multimodal studies of the contributions of amyloid and tau burden to neurodegeneration in AD, FTD and Non-AD tauopathies; Imaging of prostate-specific membrane antigen (PSMA) using [18F]DCFPyL; Ga-68 GRPR antagonist imaging; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Novel PET Radiotracerswith Potential ClinicalApplications\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface: Novel PET Radiotracers with Potential Clinical Applications\r | v | ||
| Human Epidermal Growth Factor Receptor 2-Targeted PET/Single-Photon Emission Computed Tomography Imaging of Breast Cancer: ...\r | v | ||
| Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL\r | v | ||
| Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology | v | ||
| Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand\r | vi | ||
| Magnetic Resonance–based Motion Correction for Quantitative PET in Simultaneous PET-MR Imaging | vi | ||
| PET Imaging for Early Detection of Alzheimer’s Disease: From Pathologic to Physiologic Biomarkers | vi | ||
| Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias | vi | ||
| Novel Phenotypes Detectable with PET in Mood Disorders: Elevated Monoamine Oxidase A and Translocator Protein Level | vii | ||
| PET CLINICS | viii | ||
| FORTHCOMING ISSUES | viii | ||
| October 2017 | viii | ||
| January 2018 | viii | ||
| April 2018 | viii | ||
| RECENT ISSUES | viii | ||
| April 2017 | viii | ||
| January 2017 | viii | ||
| October 2016 | viii | ||
| CME Accreditation Page | ix | ||
| PROGRAM OBJECTIVE | ix | ||
| TARGET AUDIENCE | ix | ||
| LEARNING OBJECTIVES | ix | ||
| ACCREDITATION | ix | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | ix | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | ix | ||
| TO ENROLL | x | ||
| METHOD OF PARTICIPATION | x | ||
| CME INQUIRIES/SPECIAL NEEDS | x | ||
| Preface\r | xi | ||
| Novel PET Radiotracers with Potential Clinical Applications | xi | ||
| Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer | 269 | ||
| Key points | 269 | ||
| INTRODUCTION | 269 | ||
| PET AND SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY IMAGING WITH MONOCLONAL ANTIBODIES IN HUMAN EPIDERMAL GROWTH FACTOR RECE ... | 271 | ||
| Zirconium-89-DFO-Trastuzumab | 271 | ||
| Zirconium-89-DFO-Trastuzumab to Detect Unsuspected Human Epidermal Growth Factor Receptor 2-Positive Metastatic Disease | 273 | ||
| Annotating Treatment Response with Zirconium-89-DFO-Trastuzumab | 274 | ||
| Copper-64-DOTA-Trastuzumab | 276 | ||
| Copper-64-DOTA-Trastuzumab in Metastatic Disease | 276 | ||
| Indium-111-Trastuzumab | 277 | ||
| Indium-111-DTPA-Pertuzumab | 279 | ||
| Iodine-131-SGMID Anti-Her2 VHH1 | 279 | ||
| Copper-64-MM-302 | 279 | ||
| ANTIBODY FRAGMENTS IN CLINICAL PET IMAGING | 279 | ||
| CLINICAL PET IMAGING WITH RADIOLABELED AFFIBODIES | 280 | ||
| Indium-111-ABY-025 and Gallium-68-ABY-025 | 280 | ||
| CLINICAL PET IMAGING WITH RADIOLABELED NANOBODIES | 284 | ||
| Gallium-68-Human Epidermal Growth Factor Receptor 2-Nanobody | 284 | ||
| 18F-Human Epidermal Growth Factor Receptor 2-Nanobody | 284 | ||
| SUMMARY | 285 | ||
| REFERENCES | 285 | ||
| Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL | 289 | ||
| Key points | 289 | ||
| INTRODUCTION | 289 | ||
| RADIOSYNTHESIS OF [18F]DCFPYL | 290 | ||
| PRECLINICAL STUDIES WITH [18F]DCFPYL | 290 | ||
| CLINICAL APPLICATION OF [18F]DCFPYL IN PROSTATE CANCER | 291 | ||
| CLINICAL APPLICATION OF [18F]DCFPYL IN RENAL CELL CARCINOMA | 292 | ||
| PITFALLS OF [18F]DCFPYL IMAGING | 293 | ||
| SUMMARY | 294 | ||
| ACKNOWLEDGMENTS | 294 | ||
| REFERENCES | 294 | ||
| Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology | 297 | ||
| Key points | 297 | ||
| INTRODUCTION | 297 | ||
| TOWARD GASTRIN-RELEASING PEPTIDE RECEPTOR ANTAGONISTS AND THEIR RADIOLABELED ANALOGUES FOR USE IN GASTRIN-RELEASING PEPTIDE ... | 298 | ||
| C-Terminal Alkylated-Amide [des-Met14]Bombesin Analogues\r | 299 | ||
| C-Terminal [Sta13,Met14-NH2]Bombesin Analogues | 300 | ||
| C-Terminal [des-Leu26,des-Met27-Alkylamide]Gastrin-Releasing Peptide(20–27) Analogues | 302 | ||
| THERANOSTIC PROSPECTS OF GASTRIN-RELEASING PEPTIDE RECEPTOR RADIOANTAGONISTS IN ONCOLOGY: CONCLUDING REMARKS | 302 | ||
| REFERENCES | 304 | ||
| Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105 | 311 | ||
| Key points | 311 | ||
| INTRODUCTION | 311 | ||
| BIOLOGY OF THE UROKINASE PLASMINOGEN ACTIVATOR SYSTEM | 312 | ||
| PRESENCE AND SIGNIFICANCE OF UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR IN SELECTED TUMORS | 312 | ||
| Breast Cancer | 313 | ||
| Prostate Cancer | 313 | ||
| Urinary Bladder Cancer | 313 | ||
| Glioblastoma | 313 | ||
| Pancreatic Cancer | 313 | ||
| UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR–PET IMAGING: PRECLINICAL STUDIES | 314 | ||
| CLINICAL EXPERIENCES | 315 | ||
| FUTURE DIRECTIONS | 316 | ||
| UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR–PET AS COMPANION DIAGNOSTIC | 316 | ||
| UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR–PET AS PART OF THERANOSTICS | 317 | ||
| SUMMARY | 317 | ||
| REFERENCES | 317 | ||
| Magnetic Resonance–based Motion Correction for Quantitative PET in Simultaneous PET-MR Imaging | 321 | ||
| Key points | 321 | ||
| INTRODUCTION | 321 | ||
| MAGNETIC RESONANCE-BASED MOTION MEASUREMENT AND MOTION FIELD ESTIMATION | 322 | ||
| MOTION CORRECTION IN PET RECONSTRUCTION | 323 | ||
| Reconstruct-Transform-Average Approach | 323 | ||
| Motion-Compensated Image Reconstruction Approach | 323 | ||
| IMPACT OF MOTION CORRECTION ON QUANTITATIVE PET USING PET-MAGNETIC RESONANCE | 324 | ||
| SUMMARY | 326 | ||
| ACKNOWLEDGMENTS | 326 | ||
| REFERENCES | 326 | ||
| PET Imaging for Early Detection of Alzheimer’s Disease | 329 | ||
| Key points | 329 | ||
| INTRODUCTION | 329 | ||
| PET IMAGING OF PATHOLOGIC BIOMARKERS IN ALZHEIMER'S DISEASE | 330 | ||
| Radiotracers for β-Amyloids | 330 | ||
| 11C-Pittsburgh compound-B | 330 | ||
| 18F-florbetapir | 331 | ||
| 18F-florbetaben | 331 | ||
| 18F-flutemetamol | 331 | ||
| 18F-NAV4694 | 331 | ||
| Radiotracers for Tau Protein Aggregates | 332 | ||
| 18F-T807 (18F-AV1451) and 18F-T808 | 332 | ||
| 11C-PBB3 | 333 | ||
| 18F-labeled arylquinolines (18F-THK523, 18F-THK5105, 18F-THK5117, and 18F-THK5351) | 333 | ||
| Radiotracers for Neuroinflammation Biomarkers | 334 | ||
| Radiotracers for the 18-kDa translocator protein | 334 | ||
| Radiotracers for monoamine oxidase-B | 336 | ||
| Summary | 336 | ||
| PET IMAGING OF PHYSIOLOGIC BIOMARKERS IN ALZHEIMER DISEASE | 336 | ||
| Radiotracers for the Cholinergic System | 336 | ||
| Radiotracers for acetylcholinesterase | 336 | ||
| Radiotracers for nicotinic acetylcholine receptors | 337 | ||
| Summary | 338 | ||
| Imaging of Neuronal Activity in Alzheimer Disease with 18F-Fluorodeoxyglucose | 339 | ||
| 18F-Fluorodeoxyglucose PET manifestation in Alzheimer disease dementia | 339 | ||
| 18F-Fluorodeoxyglucose PET manifestation in prodromal Alzheimer disease | 340 | ||
| 18F-Fluorodeoxyglucose PET monitoring treatment response in Alzheimer disease | 340 | ||
| Summary | 340 | ||
| Radiotracers for Imaging of Synaptic Density in Alzheimer's Disease | 340 | ||
| PERSPECTIVES | 342 | ||
| REFERENCES | 343 | ||
| Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias | 351 | ||
| Key points | 351 | ||
| WHY IS THERE A NEED FOR PATHOLOGY-SPECIFIC MOLECULAR PET IMAGING? | 351 | ||
| AMYLOID PET IMAGING | 352 | ||
| Clinical Use of Amyloid PET Imaging in Patients with Cognitive Impairment | 352 | ||
| Amyloid PET Imaging in Preclinical Alzheimer Disease and Incidental Amyloidosis | 354 | ||
| Using Amyloid PET for Treatment Development | 354 | ||
| Amyloid PET Imaging in Other Dementias | 354 | ||
| Dementia with Lewy bodies and Parkinson disease with dementia | 354 | ||
| Frontotemporal dementia | 355 | ||
| TAU PET IMAGING | 355 | ||
| Clinical Use of Tau PET Tracers in Alzheimer Disease | 355 | ||
| Tau PET imaging in Alzheimer disease | 355 | ||
| Tau PET Imaging in Frontotemporal Dementia | 356 | ||
| Tau PET Imaging in Lewy Body Disorders | 356 | ||
| Primary Age-Related Tauopathy | 357 | ||
| FUTURE DIRECTIONS | 357 | ||
| REFERENCES | 357 | ||
| Novel Phenotypes Detectable with PET in Mood Disorders | 361 | ||
| Key points | 361 | ||
| INTRODUCTION | 361 | ||
| MONOAMINE OXIDASE A | 362 | ||
| TRANSLOCATOR PROTEIN IMAGING | 365 | ||
| SUMMARY AND FUTURE DIRECTIONS | 368 | ||
| REFERENCES | 368 |